Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X:
“1 in 7 NSCLC patients on first-line immunotherapy will develop severe toxicity.
And it begins early:
- 14% severe irAEs
- ~70% within the first 3 months
- Median onset 1.4 months
Risk increase:
- ChT + ICI (HR 2.35)
- Pre-existing autoimmune disease (HR 1.25)
- Longer diagnosis to treatment interval (HR 1.50)
Risk decrease:
- Atezolizumab vs pembrolizumab (HR 0.75)
- Nivolumab (HR 0.91)
Lung, blood, GI, these lead (not rare, not late, and not random). The highest risk patients are already defined before treatment and show it within weeks.”
Title: Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer
Authors: Olajumoke Olateju, Rajender Aparasu, Meera Patel, Tyler Varisco, Chan Shen, Meghana Trivedi, Ekere Essien, J. Douglas Thornton
Other articles featuring Oscar Tahuahua on OncoDaily.